Inside the battle over COVID vaccine intellectual property rights

preview_player
Показать описание
The German pharmaceutical company that developed a COVID-19 vaccine along with Pfizer has hit out at a proposal to suspend intellectual property rights.
BioNTech says patents are not the limiting factor for the production or supply of its vaccine, and would not boost stocks around the world anytime soon.
There is a renewed push to suspend patents backed by the US president.
India and South Africa have been leading the campaign at the World Trade Organization, calling for the waiver.
But the European Union is yet to do the same.
Al Jazeera's Elizabeth Puranam reports from New Delhi, India.

#India
Рекомендации по теме
Комментарии
Автор

The vaccine research was funded by private investors. An economical option might be to license the patents on a renewable annual basis.

SusanDianeHowell
Автор

While we pray for Indians🇮🇳 to survive this virus wave,
- let's not forget how the Wuhan🇨🇳 outbreak started.

lastChang
Автор

😇😇 🤞🤞🤞 Can't wait for the 5k/day (al least!!!)🤞🤞🤞 😇😇

mattewfoss
Автор

Prays to Mother India love from Manchester England 🙏🏾❤💛💚

tyronsimpson
Автор

Mera Bharat mahaan 100 mein se 99% beyiman 🤏🏻

Jass-kf
Автор

I request to every body please protect your wallets pakistanis are here

shubhamntpc